We have a pipeline of novel, first-in-class or best-in-class drug candidates for the treatment cancers.
GPGP Tech’s research and development activities leverage its expertise in cancer to develop innovative therapeutics designed to improve patients’ lives. The company’s programs include BN0775, a novel, orally available, small molecule selective PKC delta antagonist for the treatment of KRas-mutated tumors, including non-small cell lung cancer (NSCLC), pancreatic cancer, colon cancer etc. The company is also developing two ADC drugs, Sorbitomimabl BN0775 and Maxenitumab BN0775, which target CD56 and FRa for the treatment of lung cancer.
